Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers

Clinical Cancer Research

Volumn 3, Issue 2, 1997, Pages 199-208

  Krajewski, Stanislaw ^a   Thor, Ann D ^b   Edgerton, Susan M ^b   Moore II, Dan H ^c   Krajewska, Maryla ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOBLOTTING; NEOPLASM PROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031030334     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Williams, G. T. Programmed cell death: apoptosis and oncogenesis. Cell, 65: 1097-1098, 1991.
2. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death, the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
3. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
4. Vaux, D. L. Toward an understanding of the molecular mechanisms of physiological cell death. Proc. Natl. Acad. Sci. USA, 90: 786-789, 1993.
5. Oltvai, Z. N., and Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell, 79: 189-192, 1994.
6. Oltvai, Z., Milliman, C., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
7. Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L. H., Thompson, C. B., Golemis, E., Fong, L., Wang, H-G., and Reed, J. C. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238-9242, 1994.
8. Hanada, M., Aimé-Sempé, C., Sato, T., and Reed, J. C. Structure-function analysis of bcl-2 protein: identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax. J. Biol. Chem., 270: 11962-11968, 1995.
9. Bodrug, S. E., Aimé-Sempé, C., Sato, T., Krajewski, S., Hanada, M., and Reed, J. C. Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function. Cell Death Differ., 2: 173-182, 1995.
10. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
11. Hoffman, B., and Liebermann, D. A. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene, 9: 1807-1812, 1994.
12. Thor, A. D., Moore, D. H., II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Kynch, H. T., Marcus, J. N., Schwartz, L., Chen, L-C., Mayall, B. H., Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
13. Saitoh, S., Cunningham, J., De Vries, E. M. G., McGovern, R. M., Schroeder, J. J., Hartmann, A., Blaszyk, H., Wold, L. E., Schaid, D., Sommer, S. S., Kovach, J. S. p53 gene mutations in breast cancers in mid western US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene, 9: 2869-2875, 1994.
14. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Hoffman, B., Lieberman, D., and Reed. J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
15. Selvakumaran, M., Lin, H-K., Miyashita, T., Wang, H-G., Krajewski, S., Reed, J. C., Hoffman, B., and Liebermann, D. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways. Oncogene, 9: 1791-1798, 1994.
16. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell, 80: 293-299, 1995.
17. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095-2097, 1994.
18. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
19. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C., and Harris, A. L. bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
20. Joensuu, H., Pylkkänen, L., and Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
21. Gasparini, G., Barbareschi, M., Doglioni, C., Palma, P. D., Mauri, F. A., Boracchi, P., Bevilacqua, P., Caffo, O., Morelli, L., Verderrio, P., Pezzella, F., and Harris, A. L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1: 189-198, 1995.
22. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V-M., Niskanen, E., and Reed, J. C. Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
23. Apte, S. S., Mattel, M-G., and Olsen, B. R. Mapping of the human Bax gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript. Bad. Genomics, 26: 592-594, 1995.
24. Tsujimoto, Y., and Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA, 83: 5214-5218, 1986.
25. Tanaka, S., Saito, K., and Reed, J. C. Structure-function analysis of the apoptosis-suppressing bcl-2 oncoprotein: substitution of a heterologous transmembrane domin restores function to truncated Bcl-2 proteins. J. Biol. Chem., 268: 10920-10926, 1993.
26. Zha, H., Aimé-Sempé, C., Sato, T., and Reed, J. C. Pro-apoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J. Biol. Chem., 277: 7440-7444, 1996.
27. American Joint Committee on Cancer. Manual for Staging of Cancer, pp. 127-133. Philadelphia, 1983.
28. Reed, J., Meister, L., Cuddy, M., Geyer, C., and Pleasure, D. Differential expression of the bcl-2 proto-oncogene in neuroblastomas and other human neural tumors. Cancer Res., 57: 6529-6538, 1991.
29. Krajewski, S., Bodrug, S., Gascoyne, R., Berean, K., Krajewska, M., and Reed, J. C. Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Am. J. Pathol., 145: 515-525, 1994.
30. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H-G., Irie, S., Fong, L., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res., 54: 5501-5507, 1994.
31. Krajewski, S., Bodrug, S., Krajewska, M., Shabaik, A., Gascoyne, R., Berean, K., and Reed, J. C. Immunohistochemical analysis of Mcl-1 protein in human tissues: differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am. J. Pathol., 146: 1309-1319, 1995.
32. Tan, P. E., Benz, C. C., Dollbaum, C., Moore, D. H., II, Edgerton, S. M., Zava, D. T., and Thor, A. D. Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann. Oncol., 5: 329-336, 1994.
33. Smith, P., Krohn, R., Hermanson, G., Mallia, K., Gartner, F., Prozenzano, M., Fujimoto, E., Goeke, N., Olson, B., and Klenk, D. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
34. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W., and Reed, J. C. Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res., 53: 4701-4714, 1993.
35. L is the major bcl-X mRNA form expressed during murine development and its product localizes to mitochondria. Development (Camb.), 120: 3033-3042, 1994.
36. Yang, T., Kozopas, K. M., and Craig, R. W. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J. Cell Biol., 128: 1173-1184, 1995.
37. Lithgow, T., van Driel, R., Bertram, J. F., and Strasser, A. The protein product of the oncogene hcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the other mitochondrial membrane. Cell Growth & Differ., 3: 411-417, 1994.
38. Monaghan, P., Robertson, D., Andrew, T., Amos, S., Dyer, M. J. S., Mason, D. Y., and Greaves, M. F. Ultrastructural localization of bcl-2 protein. J. Histochem. Cytochem., 40: 1819-1825, 1992.
39. Givol, I., Tsarfaty, I., Resau, J., Rulong, S., da Suva, P. P., Nasioulas, G., DuHadaway, J., Hughes, S. H., and Ewert, D. L. Bcl-2 expressed using a retroviral vector is localized primarily in the nuclear membrane and the endoplasmic reticulum of chicken embryo fibroblasts. Cell Growth & Differ., 5: 419-429, 1994.
40. Haldar, S., Jena, N., Coss, R., Sedar, A. W., Wachsbrger, P. R., Beatty, C., and Croce, C. M. Cellular localization of the bcl-2 protein and response to glucocorticoid stress. Cell Death Differ., 1: 109-115, 1994.
41. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
42. Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H-G., and Reed, J. C. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am. J. Pathol., 145: 1323-1333, 1994.
43. Teixeira, C., Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907.
44. Chou, D., Miyashita, T., Mohrenweiser, H. W., Ueki, K., Kastury, K., Druck, T., von Deimling, A., Huebner, K., Reed, J. C., and Louis, D. N. The Bax gene maps to chromosome 19q but it is not altered in human gliomas. Cancer Genet. Cytogenet., 88: 136-140, 1996.
45. Sandberg, A. A. The Chromosomes in Human Cancer and Leukemia, Ed. 2, pp. 827-831. New York: Elsevier Science Publishing, 1990.
46. Zhan, Q., Fan, S., Bae, I., Guillouf, C., Liebermann, D. A., O'Connor, P. M., and Fornace, A. J., Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743-3751, 1994.
47. Miyashita, T., Kitada, S., Krajewski, S., Home, B., Delia, D., and Reed, J. C. The Bcl-2 protein regulates the half-life of p21-Bax. J. Biol. Chem., 270: 26049-26052, 1995.
48. Doglioni, C., Dei Tos, A. P., Laurino, L., Chiarelli, C., Barbareschi, M., and Viale, G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status. Virchows Archiv., 424: 47-51, 1994.
49. Nathan, B., Gusterson, B., Jadayel, D., O'Hare, M., Anbazhagen, R., Jayatilake, H., Ebbs, S., Micklem, K., Price, K., and Gelber, R. Expression of Bcl-2 in primary breast cancer and its correlation with tumor phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann. Oncol., 5: 409-414, 1994.
50. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagenert, K., Wagener, C., Kallinich, B., Royer, H. D., and Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α. expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer, 60: 854-859, 1995.
51. Bargou, R. C., Wagener, C., Bommert, K., Mapara, M. Y., Daniel, P. T., Arnold, W., Dietel, M., Guski, H., Feller, A., Royer, H. D., and Dörken, B. Overexpression of the death-promoting gene bax-α. which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest., 97: 2651-2659, 1996.
52. Reed, J. C. Balancing cell life and death: Bax, apoptosis, and breast cancer. J. Clin. Invest., 97: 2403-2404, 1996.